Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Non-Current Debt: 2020-2022

Historic Non-Current Debt for C4 Therapeutics (CCCC) over the last 3 years, with Dec 2022 value amounting to $9.2 million.

  • C4 Therapeutics' Non-Current Debt fell 15.43% to $8.6 million in Q1 2023 from the same period last year, while for Mar 2023 it was $8.6 million, marking a year-over-year decrease of 15.43%. This contributed to the annual value of $9.2 million for FY2022, which is 14.61% down from last year.
  • C4 Therapeutics' Non-Current Debt amounted to $9.2 million in FY2022, which was down 14.61% from $10.8 million recorded in FY2021.
  • C4 Therapeutics' 5-year Non-Current Debt high stood at $10.8 million for FY2021, and its period low was $9.2 million during FY2022.
  • Moreover, its 3-year median value for Non-Current Debt was $10.1 million (2020), whereas its average is $10.0 million.
  • As far as peak fluctuations go, C4 Therapeutics' Non-Current Debt rose by 7.12% in 2021, and later decreased by 14.61% in 2022.
  • Over the past 3 years, C4 Therapeutics' Non-Current Debt (Yearly) stood at $10.1 million in 2020, then increased by 7.12% to $10.8 million in 2021, then dropped by 14.61% to $9.2 million in 2022.